Clinical Trials
Study Title:
Phase 3, Multicenter, Double Blind, Randomized, Placebo Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302)
|
For more information about the trial above please contact the study team:
|